Company Filing History:
Years Active: 2007-2012
Title: Charis Lawrenson: Innovator in Cancer Risk Assessment
Introduction
Charis Lawrenson is a notable inventor based in San Jose, CA (US). He has made significant contributions to the field of cancer research, particularly in the assessment of cancer risk. With a total of 2 patents, his work focuses on innovative methods that could potentially transform cancer diagnostics.
Latest Patents
Lawrenson's latest patents include "Pro108 antibody compositions and methods of use" and "use of Pro108 to assess cancer risk." These inventions relate to a method for assessing the risk of prostate cancer by utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination. Additionally, his work extends to assessing the risk of ovarian, colon, breast, or stomach cancer using Pro108 or specific antibodies to Pro108. The inventions provide isolated anti-cancer antigen (Pro108) antibodies that bind to Pro108 on mammalian cells in vivo. They also encompass compositions comprising an anti-Pro108 antibody and a carrier, which can be provided in an article of manufacture or a kit. Furthermore, Lawrenson's patents include methods for producing anti-Pro108 antibodies and treating Pro108-expressing cancers.
Career Highlights
Charis Lawrenson is currently associated with Diadexus, Inc., where he continues to advance his research in cancer diagnostics. His innovative approaches have the potential to significantly impact the way cancer risks are assessed and treated.
Collaborations
Some of his notable coworkers include Iris Simon and Laura Corral, who contribute to the collaborative environment at Diadexus, Inc. Their combined efforts aim to enhance the understanding and treatment of cancer.
Conclusion
Charis Lawrenson's work in developing methods for cancer risk assessment showcases his commitment to innovation in the medical field. His contributions are paving the way for more effective cancer diagnostics and treatments.